05 Compliance

Where L-isoleucine is permitted, and what the file must show

Technical document 05 · Reviewed 2026-11-19 · L-Isoleucine

On this page
  1. Four questions, one file
  2. European Union
  3. United States
  4. Contaminant limits
  5. The claim boundary
  6. The document file
  7. The checklist

Three markets, three mechanisms. The EU has no positive-list entry for amino acids, so L-isoleucine falls under general food law; the US classifies it as a dietary ingredient under DSHEA; the UK works from retained EU rules. A supplier certificate supports the file in all three, but permission, contaminant ceiling, label and claim each need their own evidence.

In one line

Amino acids sit outside the EU's Annex II positive list, so the file rests on general food law, a pre-1994 US marketing basis and retained UK rules.

Four questions, one file

A compliance file is tested four times: can the ingredient be sold here, does the finished product stay inside the contaminant limits, does the label name it correctly, and is any claim authorised and substantiated. A batch certificate helps with all four and settles none of them. Responsibility sits with the operator that places the product on the market, and these notes are a sourcing reference rather than legal advice.

European Union

Directive 2002/46/EC harmonises food supplements, and Annex II lists the vitamin and mineral substances that may be used, with their forms. Amino acids are absent. L-isoleucine therefore has no positive-list entry and sits under general food law, Regulation (EC) No 178/2002, plus national rules.

The pre-1997 history matters for the novel food question. L-isoleucine was a food constituent before 15 May 1997 and is not regarded as novel on that basis, but check the Catalogue entry for the form and route, since a new route raises a separate question. No harmonised maximum level applies. Labelling follows Regulation (EU) No 1169/2011 with the supplement particulars from Directive 2002/46/EC.

The epimer is not a grade of the same substance. L-alloisoleucine has no established food use and would need its own safety and market-entry position before a supplement could contain it.

United States

DSHEA names amino acids among the categories that qualify as a dietary ingredient, so L-isoleucine can be sold where the supplier supports the basis: an NDI notification, a GRAS conclusion, or evidence of US marketing before 15 October 1994.

Manufacturing runs under the cGMP in 21 CFR 111 and the panel follows 21 CFR 101.36. Where no Daily Value is set for the amino acid, the panel gives the amount per serving without a percentage; confirm the current format before the artwork is signed. The FDA does not approve a supplement or label before sale, so the file is the evidence.

Structure/function claims are permitted when truthful, not misleading and substantiated, with the DSHEA disclaimer and FDA notification within 30 days of first marketing; a disease claim is not. California's Proposition 65 adds a lead-exposure calculation that starts from the daily dose.

Contaminant limits

Metal limits for a supplement, by market
MetalEU · Regulation (EU) 2023/915US federalUK retained limits
Lead3.0 mg/kg in food supplementsNo numeric federal limit; 21 CFR 111 cGMP3.0 mg/kg
Cadmium1.0 mg/kg; 3.0 mg/kg for seaweed-based supplementsNo numeric federal limit; 21 CFR 111 cGMP1.0 mg/kg
Mercury0.10 mg/kgNo numeric federal limit; 21 CFR 111 cGMP0.10 mg/kg
ArsenicNo harmonised limit for supplements; the buyer sets oneNo numeric federal limit; 21 CFR 111 cGMPNo harmonised limit; the buyer sets one

The EU and UK figures apply to the food as sold, not to the drum, so a raw-material limit is a purchasing decision and leaves room for method uncertainty, other ingredients and the finished-product test. The US federal position sets no numeric ceiling, so a buyer writes a lead limit and works the Proposition 65 exposure from the dose.

The catalog limits for L-isoleucine are Pb ≤3, As ≤2, Cd ≤1 and Hg ≤0.1 mg/kg. Lead, cadmium and mercury sit at or below the EU and UK ceilings. Arsenic is a buyer-set limit in both regimes, so the 2 mg/kg figure on the specification is a purchasing choice rather than a legal requirement.

The claim boundary

In the EU and the UK an authorised claim has to appear in the Register, and Regulation (EC) No 1924/2006 requires it to be truthful, clear and substantiated. As of this review the EU Register carries no authorised claim for L-isoleucine as such, so no body-function claim should be attached unless a current entry is found.

Protein claims are the usual trap. A claim about protein describes a food that is a source of protein; it does not transfer to a free amino acid that happens to be a protein component. An amino acid content statement is a composition statement, and it still has to be accurate.

In the US the route is a structure/function claim with the disclaimer and the notification; a disease claim is outside it. The GB Register is the UK reference. In all three markets the claim must describe the product rather than a disease, and the evidence has to sit in the file.

The panel names the ingredient rather than the category. “L-isoleucine” belongs on the label with the amount per serving, on the same basis as the certificate; a blend declares its ratio and still names the amino acid. A drum of the epimer cannot be declared as L-isoleucine, and a DL mixture has to say on the panel that it is DL.

The document file

Documents to hold for an L-isoleucine lot
DocumentWhat it answersMarket
Batch certificate of analysisReleased against the agreed limits, with method and resultAll
SpecificationLimits, methods, dried basis, mesh and versionAll
Technical data sheetSolubility, mesh, flow, handling and packAll
Safety data sheetHazard and handling informationAll
Allergen and GMO statementsDeclarations for the panel and the fileEU, UK, US
Market-entry statementNovel food, NDI or pre-1994 position for the formEU, UK, US
Origin and route statementTraceability and the fermentation or hydrolysis routeAll
Metals and micro reportsThe contaminant and hygiene envelopeAll

The checklist

  1. Name the form and match CAS 73-32-5; the epimer and the DL mixture are different substances.
  2. Confirm the market-entry position for that form, including Member State rules and the GB Register.
  3. Set raw-material limits below the finished-product ceiling, and set an arsenic limit because neither the EU nor the UK does.
  4. Work the daily dose through the contaminant figures and, for the US, through Proposition 65.
  5. Match the label name and amount to the certificate and the purchase order on the same basis.
  6. Test every claim against the Register or the DSHEA route and keep the substantiation.
  7. File the documents against the lot number rather than the product name.
  8. Ask for the manufacturing route and the animal-derived input statement, since fermentation and hydrolysis carry different declarations.

Tie the file to the lot: the tests on the COA page, the form on the grade page and the epimer page, the proof on the identity page. The product hub holds the catalog specification, the quality page the release workflow; the ICP-MS note explains the metals, and heavy metals is in the glossary.

Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.

Request a quotation